Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-κB signaling pathway.

Qiu X, Du Y, Lou B, Zuo Y, Shao W, Huo Y, Huang J, Yu Y, Zhou B, Du J, Fu H, Bu X.

J Med Chem. 2010 Dec 9;53(23):8260-73. doi: 10.1021/jm1004545. Epub 2010 Nov 11.

2.

Synthesis, cytotoxicity of new 4-arylidene curcumin analogues and their multi-functions in inhibition of both NF-κB and Akt signalling.

Zuo Y, Huang J, Zhou B, Wang S, Shao W, Zhu C, Lin L, Wen G, Wang H, Du J, Bu X.

Eur J Med Chem. 2012 Sep;55:346-57. doi: 10.1016/j.ejmech.2012.07.039. Epub 2012 Jul 31.

PMID:
22889562
3.

Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3,5-bis(2-flurobenzylidene)piperidin-4-one (EF24), a novel monoketone analog of curcumin.

Kasinski AL, Du Y, Thomas SL, Zhao J, Sun SY, Khuri FR, Wang CY, Shoji M, Sun A, Snyder JP, Liotta D, Fu H.

Mol Pharmacol. 2008 Sep;74(3):654-61. doi: 10.1124/mol.108.046201. Epub 2008 Jun 24.

4.

Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-κB inhibition and p53 reactivation in human lung cancer cells.

Zhou B, Zuo Y, Li B, Wang H, Liu H, Wang X, Qiu X, Hu Y, Wen S, Du J, Bu X.

Mol Cancer Ther. 2013 Aug;12(8):1381-92. doi: 10.1158/1535-7163.MCT-12-1057. Epub 2013 May 21.

5.

Synthesis, characterization and in vitro anticancer activity of C-5 curcumin analogues with potential to inhibit TNF-α-induced NF-κB activation.

Anthwal A, Thakur BK, Rawat MS, Rawat DS, Tyagi AK, Aggarwal BB.

Biomed Res Int. 2014;2014:524161. doi: 10.1155/2014/524161. Epub 2014 Jul 24.

6.

Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties.

Olivera A, Moore TW, Hu F, Brown AP, Sun A, Liotta DC, Snyder JP, Yoon Y, Shim H, Marcus AI, Miller AH, Pace TW.

Int Immunopharmacol. 2012 Feb;12(2):368-77. doi: 10.1016/j.intimp.2011.12.009. Epub 2011 Dec 22.

7.

Characterization of a novel curcumin analog P1 as potent inhibitor of the NF-κB signaling pathway with distinct mechanisms.

Peng YM, Zheng JB, Zhou YB, Li J.

Acta Pharmacol Sin. 2013 Jul;34(7):939-50. doi: 10.1038/aps.2013.2. Epub 2013 Apr 22.

8.

Structure-activity relationship studies of curcumin analogues.

Fuchs JR, Pandit B, Bhasin D, Etter JP, Regan N, Abdelhamid D, Li C, Lin J, Li PK.

Bioorg Med Chem Lett. 2009 Apr 1;19(7):2065-9. doi: 10.1016/j.bmcl.2009.01.104. Epub 2009 Feb 5.

PMID:
19249204
9.

Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.

Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE.

Clin Cancer Res. 2005 Oct 15;11(20):7490-8.

10.

A novel monocarbonyl analogue of curcumin, (1E,4E)-1,5-bis(2,3-dimethoxyphenyl)penta-1,4-dien-3-one, induced cancer cell H460 apoptosis via activation of endoplasmic reticulum stress signaling pathway.

Wang Y, Xiao J, Zhou H, Yang S, Wu X, Jiang C, Zhao Y, Liang D, Li X, Liang G.

J Med Chem. 2011 Jun 9;54(11):3768-78. doi: 10.1021/jm200017g. Epub 2011 May 16.

PMID:
21504179
11.

Identification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase.

Yue X, Zuo Y, Ke H, Luo J, Lou L, Qin W, Wang Y, Liu Z, Chen D, Sun H, Zheng W, Zhu C, Wang R, Wen G, Du J, Zhou B, Bu X.

Biochem Pharmacol. 2017 Aug 1;137:29-50. doi: 10.1016/j.bcp.2017.04.032. Epub 2017 May 3.

PMID:
28476333
12.

Inhibition of the NF-κB signaling pathway by a novel heterocyclic curcumin analogue.

Katsori AM, Palagani A, Bougarne N, Hadjipavlou-Litina D, Haegeman G, Vanden Berghe W.

Molecules. 2015 Jan 8;20(1):863-78. doi: 10.3390/molecules20010863.

13.

17-Acetoxyjolkinolide B irreversibly inhibits IkappaB kinase and induces apoptosis of tumor cells.

Yan SS, Li Y, Wang Y, Shen SS, Gu Y, Wang HB, Qin GW, Yu Q.

Mol Cancer Ther. 2008 Jun;7(6):1523-32. doi: 10.1158/1535-7163.MCT-08-0263.

15.

Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors.

Qiu X, Liu Z, Shao WY, Liu X, Jing DP, Yu YJ, An LK, Huang SL, Bu XZ, Huang ZS, Gu LQ.

Bioorg Med Chem. 2008 Sep 1;16(17):8035-41. doi: 10.1016/j.bmc.2008.07.054. Epub 2008 Jul 24.

PMID:
18678491
16.

Design, synthesis, anti-lung cancer activity, and chemosensitization of tumor-selective MCACs based on ROS-mediated JNK pathway activation and NF-κB pathway inhibition.

Chen L, Li Q, Weng B, Wang J, Zhou Y, Cheng D, Sirirak T, Qiu P, Wu J.

Eur J Med Chem. 2018 May 10;151:508-519. doi: 10.1016/j.ejmech.2018.03.051. Epub 2018 Apr 6.

PMID:
29655083
17.
18.

Curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-κB signaling and induces apoptosis.

Sato A, Kudo C, Yamakoshi H, Uehara Y, Ohori H, Ishioka C, Iwabuchi Y, Shibata H.

Cancer Sci. 2011 May;102(5):1045-51. doi: 10.1111/j.1349-7006.2011.01886.x. Epub 2011 Feb 24.

19.

Identification of angular naphthopyrones from the Philippine echinoderm Comanthus species as inhibitors of the NF-κB signaling pathway.

Chovolou Y, Ebada SS, Wätjen W, Proksch P.

Eur J Pharmacol. 2011 Apr 25;657(1-3):26-34. doi: 10.1016/j.ejphar.2011.01.039. Epub 2011 Feb 4.

PMID:
21296074
20.

Design, synthesis, and biological evaluation of novel EF24 and EF31 analogs as potential IκB kinase β inhibitors for the treatment of pancreatic cancer.

Xie X, Tu J, You H, Hu B.

Drug Des Devel Ther. 2017 May 12;11:1439-1451. doi: 10.2147/DDDT.S133172. eCollection 2017.

Supplemental Content

Support Center